Viridian Therapeutics, Inc.
VRDN
$12.38
-$0.43-3.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -79.04% | -19.24% | -60.91% | -18.03% | 28.77% |
| Total Depreciation and Amortization | -19.31% | -93.43% | 26.53% | 7.58% | 38.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.66% | -74.19% | -57.71% | -46.82% | -34.08% |
| Change in Net Operating Assets | -179.45% | -91.81% | 172.69% | 337.02% | 20.84% |
| Cash from Operations | -104.88% | -92.98% | -73.68% | -1.87% | 27.03% |
| Capital Expenditure | -- | -137.50% | 27.48% | 68.58% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 170.01% | 62.98% | -274.16% | 51.25% | -985.32% |
| Cash from Investing | 169.95% | 62.93% | -276.24% | 52.23% | -975.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.98% | -72.62% | 24,119.88% | -93.16% | 2,184.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.01% | 88.90% | -2,848.05% | -- | -- |
| Cash from Financing | -94.80% | -82.14% | 1,485.19% | -96.48% | 2,058.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 248.59% | -1,048.49% | 277.93% | 1,218.35% | 83.32% |